Data / Drug companies / Natco Pharma Limited
Natco Pharma Limited: 53 products in the FDA NDC directory, labeler code 63850
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Natco Pharma Limited (labeler code 63850) lists 53 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 34 bulk ingredients, 19 prescription drugs. Its main marketing category is bulk ingredients. The newest product started marketing on May 16, 2026.
The request: Watch Natco Pharma Limited (FDA labeler code 63850): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63850
- Products in commercial distribution
- 53
- Packages
- 71
- Finished drugs by generic name
- 7
- Prescription products
- 19
- Over the counter products
- 0
- Flagged as original packager
- 19 of 19 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 23, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 34 | 64.2% |
| Generic drugs (ANDA) | 19 | 35.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 34 | 64.2% |
| Prescription drugs | 19 | 35.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Everolimus | 8 | 15 |
| Pomalidomide | 4 | 12 |
| Ondansetron tablets | 2 | 1 |
| Trihexyphenidyl hydrochloride | 2 | 8 |
| Letrozole | 1 | 17 |
| Granisetron hydrochloride | 1 | 8 |
| Anastrozole | 1 | 22 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 33 | 62.3% |
| Tablet | 12 | 22.6% |
| Capsule | 4 | 7.5% |
| Tablet, film coated | 3 | 5.7% |
| Injection | 1 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Kinase Inhibitor | 8 |
| mTOR Inhibitor Immunosuppressant | 8 |
| Thalidomide Analog | 4 |
| Serotonin-3 Receptor Antagonist | 3 |
| Aromatase Inhibitor | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Imatinib | 63850-8126 | Powder | Bulk ingredients | May 16, 2026 |
| Pomalidomide | 63850-0134 | Capsule | Generic drugs (ANDA) | November 1, 2025 |
| Pomalidomide | 63850-0133 | Capsule | Generic drugs (ANDA) | November 1, 2025 |
| Pomalidomide | 63850-0132 | Capsule | Generic drugs (ANDA) | November 1, 2025 |
| Pomalidomide | 63850-0131 | Capsule | Generic drugs (ANDA) | November 1, 2025 |
| Venetoclax | 63850-8103 | Powder | Bulk ingredients | November 29, 2023 |
| Acalabrutinib dihydrate | 63850-8113 | Powder | Bulk ingredients | November 25, 2023 |
| Idelalisib | 63850-8098 | Powder | Bulk ingredients | November 25, 2023 |
| Ruxolitinib phosphate | 63850-8125 | Powder | Bulk ingredients | November 24, 2023 |
| Everolimus | 63850-0061 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Everolimus | 63850-0107 | Tablet | Generic drugs (ANDA) | May 20, 2021 |
| Everolimus | 63850-0064 | Tablet | Generic drugs (ANDA) | May 20, 2021 |
| Everolimus | 63850-0063 | Tablet | Generic drugs (ANDA) | May 20, 2021 |
| Everolimus | 63850-0062 | Tablet | Generic drugs (ANDA) | May 20, 2021 |
| Nilotinib hydrochloride monohydrate | 63850-8106 | Powder | Bulk ingredients | May 19, 2021 |
| Lapatinib ditosylate anhydrous | 63850-7421 | Powder | Bulk ingredients | May 17, 2021 |
| Everolimus | 63850-0060 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Everolimus | 63850-0059 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Everolimus | 63850-0058 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Ibrutinib | 63850-8089 | Powder | Bulk ingredients | January 4, 2020 |
| Gefitinib | 63850-8070 | Powder | Bulk ingredients | January 4, 2020 |
| Sugammadex sodium | 63850-8099 | Powder | Bulk ingredients | January 30, 2019 |
| Chloroquine phosphate | 63850-8080 | Powder | Bulk ingredients | March 1, 2018 |
| Teriflunomide | 63850-8081 | Powder | Bulk ingredients | December 9, 2017 |
| Glatiramer acetate | 63850-4035 | Injection | Bulk ingredients | December 9, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.